Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.

Sampath, Deepak; Zabka, Tanja S; Misner, Dinah L; O'Brien, Thomas; Dragovich, Peter S

Sampath, Deepak; Zabka, Tanja S; Misner, Dinah L; O'Brien, Thomas; Dragovich, Peter S.

Afiliación

Sampath D; Department of Translational Oncology, Genentech Research and Early Development, South San Francisco, CA 94080, USA. Electronic address: dsampath@gene.com.
Zabka TS; Department of Safety Assessment, Genentech Research and Early Development, South San Francisco, CA 94080, USA.
Misner DL; Department of Safety Assessment, Genentech Research and Early Development, South San Francisco, CA 94080, USA.
O'Brien T; Department of Translational Oncology, Genentech Research and Early Development, South San Francisco, CA 94080, USA.
Dragovich PS; Department of Discovery Chemistry, Genentech Research and Early Development, South San Francisco, CA 94080, USA.

Pharmacol Ther ; 151: 16-31, 2015 Jul.

Article en En | MEDLINE | ID: mdl-25709099

Asunto(s)

Antineoplásicos/uso terapéutico; Neoplasias/tratamiento farmacológico; Nicotinamida Fosforribosiltransferasa/antagonistas & inhibidores; Animales; Antineoplásicos/farmacología; Antineoplásicos/toxicidad; Ensayos Clínicos como Asunto; Interacciones Farmacológicas; Resistencia a Antineoplásicos; Humanos; Modelos Moleculares; Neoplasias/enzimología; Niacina/farmacología; Niacina/uso terapéutico; Nicotinamida Fosforribosiltransferasa/metabolismo; Relación Estructura-Actividad

Palabras clave

NAD; NAMPT; NAPRT1; Targeted agents; Tumor metabolism

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Nicotinamida Fosforribosiltransferasa / Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Pharmacol Ther Año: 2015 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google